VRDN - Viridian Therapeutics, Inc. Stock Price, Fair Value and News

$19.03+0.30 (+1.60%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VRDN Price Action

Last 7 days

6.6%

Last 30 days

-3.8%

Last 90 days

-14.7%

Trailing 12 Months

-10.9%

VRDN RSI Chart

VRDN Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-5.86

Price/Sales (Trailing)

1.1K

Price/Free Cashflow

-7.64

VRDN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VRDN Fundamentals

VRDN Revenue

Revenue (TTM)

1.8M

Rev. Growth (Yr)

87.2%

Rev. Growth (Qtr)

0.05%

VRDN Earnings

Earnings (TTM)

-257.1M

Earnings Growth (Yr)

-60.91%

Earnings Growth (Qtr)

-18%

VRDN Profitability

Operating Margin

-42.63%

Return on Equity

-36.34%

Return on Assets

-33.31%

Free Cashflow Yield

-13.1%

VRDN Investor Care

Shares Dilution (1Y)

50.63%

Diluted EPS (TTM)

-4.3

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	1.7M	874.0K	1.7M	1.8M
2021	1.7M	2.6M	2.8M	3.0M
2020	4.9M	2.6M	1.9M	1.1M
2019	4.0M	4.3M	4.1M	4.5M
2018	8.3M	9.8M	9.1M	8.4M
2017	3.0M	2.6M	3.3M	4.0M
2016	2.8M	3.2M	3.6M	3.5M
2015	3.9M	3.4M	3.0M	2.5M
2014	4.3M	4.8M	5.7M	4.3M
2013	0	4.4M	4.3M	4.3M
2012	0	0	0	4.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.

CEO	Mr. Scott D. Myers M.B.A.
WEBSITE	viridiantherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	86

Viridian Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Viridian Therapeutics, Inc.? What does VRDN stand for in stocks?

VRDN is the stock ticker symbol of Viridian Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Viridian Therapeutics, Inc. (VRDN)?

As of Fri Dec 20 2024, market cap of Viridian Therapeutics, Inc. is 1.51 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VRDN stock?

You can check VRDN's fair value in chart for subscribers.

Is Viridian Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether VRDN is over valued or under valued. Whether Viridian Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Viridian Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VRDN.

What is Viridian Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, VRDN's PE ratio (Price to Earnings) is -5.86 and Price to Sales (PS) ratio is 1.14 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VRDN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Viridian Therapeutics, Inc.'s stock?

In the past 10 years, Viridian Therapeutics, Inc. has provided -0.279 (multiply by 100 for percentage) rate of return.